Last reviewed · How we verify
Imjudo (TREMELIMUMAB)
Tremelimumab-actl binds to CTLA-4, blocking its interaction with CD80 and CD86, thereby enhancing T-cell activation and reducing tumor growth.
At a glance
| Generic name | TREMELIMUMAB |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | CTLA-4-directed Blocking Antibody [EPC] |
| Target | CTLA-4 |
| Modality | Monoclonal antibody |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2022 |
| Annual revenue | 400 |
Mechanism of action
Tremelimumab-actl is designed to bind to CTLA-4, a protein that normally inhibits T-cell activity. By blocking CTLA-4, the drug removes this inhibition, leading to increased T-cell activation and proliferation, which can help combat tumors.
Approved indications
- Liver cell carcinoma
- Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations
- Non-small cell lung cancer, negative for epidermal growth factor receptor expression
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Decreased appetite
- Rash
- Abdominal pain
- Musculoskeletal pain
- Pruritus
- Hemorrhage
- Neutropenia
- Leukopenia
- Lymphocytopenia
Key clinical trials
- Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer (PHASE2)
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations
- A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (PHASE2)
- Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer (PHASE2)
- IIT2025-03-YANG-LIFT-HCC (PHASE2)
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (PHASE2)
- Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens (PHASE1)
Patents
| Patent | Expiry | Type |
|---|---|---|
| Biologic Exclusivity |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imjudo CI brief — competitive landscape report
- Imjudo updates RSS · CI watch RSS
- AstraZeneca portfolio CI